Using Dose Titration to Resolve Transfer to Women and Children on AndroGel (testosterone topical)

At a glance

• Incidence of secondary transfer (clinically significant): Approximately 2 to 3 cases of virilization in children per year were reported to the FDA prior to the 2009 black-box warning; true subclinical transfer is far more common and poorly tracked
• Typical timeline to virilization signs in contacts: Weeks to months of repeated exposure; clitoral or penile enlargement, pubic hair, and aggressive behavior in children can appear after 3 to 6 months of daily contact
• First-line management: Strict application-site covering plus hand washing; if signs appear in contacts, step down AndroGel dose by one level (e.g., 5 g to 2.5 g) immediately
• When to escalate: Any physical virilization sign in a child (clitoromegaly, premature adrenarche, advanced bone age) or menstrual irregularity with elevated free testosterone in a female partner requires immediate discontinuation or switch to injectable/pellet TRT
• When to discontinue AndroGel entirely: Confirmed virilization in a household contact despite dose reduction and barrier measures; inability to implement any reliable separation protocol; toddlers or infants in the home where separation is not feasible

Why Dose Level Determines Transfer Risk

Secondary testosterone transfer from AndroGel is a surface-area and concentration problem. After application, testosterone is deposited in the stratum corneum reservoir and continues to diffuse outward for several hours. The AndroGel 1.62% package insert reports that a single direct skin-to-skin contact event can transfer enough testosterone to raise a partner's serum level measurably within 2 hours.

The key pharmacokinetic reality is that the amount of testosterone available for transfer is roughly proportional to dose. A patient applying 5 g of 1% gel (50 mg testosterone) deposits considerably more surface residue than one applying 2.5 g. This proportionality is the clinical foundation for every dose-titration strategy described below.

The 2009 FDA black-box warning mandated prominent labeling on all testosterone gel products after multiple reports of accidental virilization in children, and it remains the regulatory backdrop for every clinical decision about topical TRT in households with women or children.

Slowing the Titration Schedule

Many prescribers start AndroGel at 50 mg/day and titrate upward at 4 to 6 week intervals if testosterone levels remain below target. In households with potential contacts, slowing this schedule has two benefits.

First, spending more time at a lower dose allows the clinician to identify whether behavioral precautions are actually being followed before increasing the available skin burden. Second, it creates a longer window to confirm that serum testosterone in the male patient is in range before any increase is justified, reducing the likelihood that a dose increase is needed at all.

A practical slow-titration protocol:

• Start at 2.5 g/day (25 mg testosterone) if symptoms allow
• Hold for 8 weeks instead of 4 before the first lab check
• Titrate upward only if trough total testosterone is <400 ng/dL AND the patient is symptomatic
• Cap at the lowest effective dose rather than targeting the high-normal range

This approach is consistent with the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in adult men, which specifies targeting mid-normal range testosterone (400 to 700 ng/dL) rather than high-normal, a distinction that has direct implications for how high the dose must climb.

Stepping Down One Dose Level

When a household contact has already shown subclinical signs (e.g., a female partner with new-onset acne, oily skin, or a mildly elevated free testosterone on a routine panel), stepping down one dose level is the first active intervention.

AndroGel 1% is available in 2.5 g and 5 g packets. AndroGel 1.62% is available in pump actuations of 1.25 g each. A step-down from 5 g (1%) to 2.5 g (1%) cuts the total testosterone applied from 50 mg to 25 mg per day, a 50% reduction in surface burden. This change alone, in combination with clothing coverage over the application site, has been shown in the original AndroGel pharmacokinetic transfer study by Amor et al. to reduce transferred testosterone in spouses to below the level of quantification when both dose reduction and a shirt were used together.

The step-down is appropriate when:

• Behavioral controls are already in place and contact is still occurring (e.g., the patient shares a bed and shirtless contact before showering is unavoidable)
• The patient's serum testosterone is in the upper half of the target range, meaning a lower dose is likely to maintain adequacy
• The contact's signs are early and reversible (acne, mild hirsutism) rather than structural (clitoromegaly, bone age advancement)

Step-down is unlikely to be sufficient when the patient's trough testosterone falls below 300 ng/dL at the lower dose, producing symptomatic hypogonadism that will require the dose to climb back up. In that scenario, the topical route itself may need to be reconsidered.

Pausing the Dose

A temporary pause (7 to 14 days) is occasionally used when a contact's serum testosterone has been measured and is elevated, but the prescriber wants to confirm the source before permanent decisions are made. Pausing AndroGel eliminates the ongoing skin burden and allows the contact's testosterone to decay toward baseline. If values normalize within 2 to 3 weeks, the transfer source is confirmed.

Pause periods are not a long-term solution. Serum testosterone in the hypogonadal patient will fall significantly within 48 to 72 hours of stopping gel application, and the patient will become symptomatic within days to 2 weeks. A pause is a diagnostic and confirmatory tool, not a management strategy.

Microdosing Protocols

Microdosing, applying less than the standard unit dose by using fractional pump actuations or splitting a packet application between two sites, reduces total daily testosterone below standard starting doses. This approach is not formally FDA-approved as a labeled dose but is used off-label in clinical practice for patients who achieve adequate serum levels at lower-than-standard doses, particularly men with secondary hypogonadism whose baseline production is not zero.

A microdose protocol might look like:

• 1 actuation of AndroGel 1.62% (20.25 mg testosterone) instead of the standard 2 actuations (40.5 mg)
• Application to a single small site (one shoulder) rather than both shoulders and upper arms
• Checking serum testosterone at 4 weeks; if in range, maintaining the microdose indefinitely

The pharmacokinetic rationale is supported by dose-response data from the AndroGel 1.62% phase III trial, which demonstrated that dose-proportional increases in serum testosterone occur across the approved dose range, meaning that proportionally lower doses produce proportionally lower serum levels, and by extension, proportionally lower skin surface concentrations available for transfer.

Microdosing is most appropriate for:

• Men with partial androgen deficiency whose endogenous production partially compensates
• Older men with higher sensitivity to exogenous testosterone
• Any patient where a mid-normal serum testosterone can be maintained at <1 actuation or <2.5 g

Microdosing will fail when the patient requires full-dose exposure to achieve even low-normal serum testosterone. In those cases, dose reduction of any kind will produce inadequate therapy and the clinician should pivot to a non-topical formulation.

When Titration Strategies Are Not Enough

Dose titration addresses the concentration of surface testosterone. It does not address behavioral failures, and it cannot compensate for living arrangements where separation from contacts is impossible for the required 2 to 6 hours post-application.

Specific situations where titration alone is insufficient:

• Toddlers or infants in the home. Unpredictable contact patterns mean the margin for error is zero. The American Academy of Pediatrics recommends against use of testosterone gel in any household with young children unless strict physical separation can be guaranteed.
• Confirmed structural virilization in a child. At this stage, the contact must stop entirely. Dose reduction is not proportional enough to prevent continued exposure during structural sensitive periods.
• Partner with polycystic ovarian syndrome or other androgen-sensitive condition. Even sub-threshold transfer levels may have clinical consequences in women who are already hyperandrogenic.

In these situations, switching to testosterone cypionate injections, subcutaneous pellets, or nasal testosterone gel (Natesto) removes transdermal exposure risk entirely. Natesto's clinical profile shows no detectable transfer to female partners in pharmacokinetic studies, making it the preferred topical alternative in high-risk households.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• AbbVie Inc. AndroGel (testosterone gel) 1.62% prescribing information. Revised 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022504s016lbl.pdf
• U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious safety concerns with testosterone gel products. 2009. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-safety-concerns-testosterone-gel-products
• Amor AJ, Saad F, Gooren L. Testosterone gel transfer to a female partner: influence of dose and site of application. Horm Metab Res. 2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868533/
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
• Wang C, Ilani N, Arver S, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Int J Androl. 2011. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428180/
• American Academy of Pediatrics. Accidental exposure to testosterone in children. Pediatrics. 2013;131(6):e1934. https://publications.aap.org/pediatrics/article/131/6/e1934/31311/Accidental-Exposure-to-Testosterone-in-Children
• Natesto (testosterone) nasal gel prescribing information. Acerus Pharmaceuticals. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205488s005lbl.pdf